MedPath

Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease

Not Applicable
Active, not recruiting
Conditions
Parkinson Disease
Registration Number
NCT04547712
Lead Sponsor
MedtronicNeuro
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Active, not recruiting
Sex
All
Target Recruitment
85
Inclusion Criteria

Inclusion Criteria:<br><br>General<br><br> 1. Subject has idiopathic Parkinson's disease<br><br> 2. Subject is implanted with Percept PC (Model B35200) and Medtronic Deep Brain<br> Stimulation (DBS) leads (Model 3387, 3389, B33005 or B33015) and extensions (Model<br> 37085, 37086, or B34000) bilaterally in the same target (physician confirmed),<br> subthalamic nucleus (STN) or Globus Pallidus (GPi)<br><br> 3. In the opinion of the investigator, the subject responds to DBS Therapy.<br><br> 4. Based on the opinion of the investigator, the subject's cDBS parameters and PD<br> medications are stable and expected to remain stable from enrollment through the end<br> of the aDBS Evaluation phase<br><br> 5. (Primary Cohort) Subject is configured to ring mode monopolar or dual monopolar<br> stimulation using contacts 1 and/or 2 (9 and/or 10) on at least one side.<br><br> 5. (Directional Stimulation Cohort) Subject is configured to directional monopolar or<br> dual monopolar stimulation using contacts 1 and/or 2 (9 and/or 10) 6. Subject is<br> willing and able to attend all study-required visits and complete the study<br> procedures (e.g. 1-month recall questionnaires, MDS-UPDRS III) 7. Subject has the<br> ability to understand and provide written informed consent for participation in the<br> study prior to the study-related procedures being conducted 8. Subject is a male or<br> non-pregnant female. If female of child-bearing potential, and if sexually active,<br> must be using, or agree to use, a medically-acceptable method of birth control as<br> confirmed by the investigator 9. For subjects with the SenSight system: Subject is<br> configured to the following stimulation rates: 55, 85, 110, 125, 145, 164 or 180 Hz<br> (as required for sensing/aDBS)<br><br>Local Field Potential (LFP) Screening Inclusion Criteria<br><br> 1. Subject has required Alpha-Beta band (8-30 Hz) amplitude detected on either left<br> and/or right DBS leads<br><br>Exclusion Criteria:<br><br> 1. Subject and/or caregiver is unable to utilize the patient programmer<br><br> 2. Subject has more than one lead in each hemisphere of the brain<br><br> 3. Subject has cortical leads or additional unapproved hardware implanted in the brain<br><br> 4. Subject has more than one INS<br><br> 5. At enrollment, the subject's INS has a predicted battery life of <1 year<br><br> 6. Subject has Beck Depression Inventory II (BDI-II) > 25<br><br> 7. Subject requires diathermy, transcranial magnetic stimulation (TMS), or<br> electroconvulsive therapy (ECT)<br><br> 8. Subject has a metallic implant in the head, (eg, aneurysm clip, cochlear implant)<br><br> 9. Subject has, or plans to obtain, an implanted electrical stimulation medical device<br> anywhere in the body (eg, cardiac pacemaker, defibrillator, spinal cord stimulator)<br><br> 10. Subject has, or plans to obtain, an implanted medication pump for the treatment of<br> Parkinson's disease (eg, DUOPATM infusion pump) and/or portable infusion pump<br><br> 11. Based on the opinion of the investigator, the subject has an abnormal neurological<br> examination that would preclude them from study participation<br><br> 12. Subject is breast feeding<br><br> 13. Subject is under the age of 18 years<br><br> 14. Subject is currently enrolled in or plans to enroll in any concurrent drug and/or<br> device study that may confound the results of this study as determined by the<br> Medtronic study team<br><br> 15. Subject is unable to use or tolerate wearable<br><br> 16. Subjects with signal artifact on all 6 aDBS sense pathways (3 each on both DBS<br> leads) which preclude the clinician from setting thresholds

Exclusion Criteria

Not provided

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
On time without troublesome dyskinesia
Secondary Outcome Measures
NameTimeMethod
Stimulation energy use
© Copyright 2025. All Rights Reserved by MedPath